After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Salt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that its Board ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...

Using ChatGPT is a lot simpler than you think, and there are many ways to make it work best for you. Amanda Smith is a freelance journalist and writer. She reports on culture, society, human interest ...

The trend of AI researchers developing new, small open source generative models that outperform far larger, proprietary peers continued this week with yet another staggering advancement. The goal is ...

The very first game on the NBA's 2025 preseason slate is a battle between the Sixers and the New York Knicks on Thursday afternoon in Abu Dhabi, the first of two exhibitions between the teams before ...

As you’ve probably heard, if not also experienced, AI is reshaping how we work. If you happen to be a senior professional with sufficient reputational capital, status, and a deep social network, you ...

Worker confidence in the ability to find a job has hit a record low. Employers in nearly every industry have cut back on hiring, according to the latest data, leaving job seekers with fewer places to ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) shares are volatile on Tuesday following the release of the company’s second-quarter financial results. Here’s what you need to know. RXRX is hovering near ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

For this week’s Open Questions column, Dhruv Khullar is filling in for Joshua Rothman. When David Fajgenbaum was a twenty-five-year-old medical student, at the University of Pennsylvania, he started ...

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...